Browse studies

Find your next paid study

7 recruiting studies matching your filters

A Phase II Study of Allogeneic Hematopoietic Stem Cell Transplant for Patients With Inborn Errors of Immunity

Background: During a transplant, blood stem cells from one person are given to someone else. The cells grow into the different cells that make up the immune s…

Lymphoproliferative DisordersAutoimmune LymphoproliferativeImmune System Diseases+2 more

Estimated

~$10 – $5,625

National Cancer Institute (NCI)NCT04339777

Phase 2

Pilot Trial of Allogeneic Blood or Marrow Transplantation for Primary Immunodeficiencies

Background: Allogeneic blood or marrow transplant is when stem cells are taken from one person s blood or bone marrow and given to another person. Researchers…

Primary T-cell Immunodeficiency DisordersCommon Variable ImmunodeficiencyImmune System Diseases+2 more

Estimated

~$10 – $5,625

National Cancer Institute (NCI)NCT02579967

Phase 3

Multicenter, Open-Label, Phase 3 Study of Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Subjects With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure of Rituximab or Rituximab and Chemotherapy

The purpose of this study is to determine the clinical benefit and characterize the safety profile of tabelecleucel for the treatment of Epstein-Barr virus-ass…

Epstein-Barr Virus+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD)Solid Organ Transplant ComplicationsLymphoproliferative Disorders+2 more

Estimated

~$10 – $7,500

Pierre Fabre MedicamentNCT03394365

Phase 1

A Phase 1 Study to Evaluate the Safety of KLN-1010, a Novel, In Vivo Gene Therapy to Generate Anti-B Cell Maturation Antigen (Anti-BCMA) Chimeric Antigen Receptor-T Cells (CAR-T) in Patients With Relapsed and Refractory Multiple Myeloma

The goal of this clinical trial is to evaluate the safety, tolerability, and recommended Phase 2 Dose (RP2D) of KLN-1010 in patients with relapsed or refractor…

Multiple Myeloma in RelapseMyeloma MultipleMultiple Myeloma Progression+11 more

Estimated

~$10 – $8,750

Kelonia Therapeutics, Inc.NCT07075185

Establishing a Tumor Bank and Initial Analysis of Germline and Tumor-Related Genetic Alterations in Families With Multiple Lymphoproliferative Malignancies

The purpose of this study is to investigate possible genetic factors that contribute to the development of lymphomas. The databank will be used to determine wh…

Non-Hodgkin's LymphomaHodgkin's DiseaseLeukemia, Lymphocytic, Chronic+1 more

Estimated

~$10 – $1,125

Dana-Farber Cancer InstituteNCT00131014

Phase 1

A Phase I/II, Open-label, Multicenter Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of Anti-GPRC5D CAR-T Cell Product (OriCAR-017) in Subjects With Relapsed/Refractory Multiple Myeloma.

The is a first clinical study for Oricell Therapeutics Inc. in the United States to evaluate the safety, PK, PD and preliminary efficacy of our anti-GPRC5D cel…

Neoplasms, Plasma CellNeoplasms by Histologic TypeNeoplasms+11 more

Estimated

~$10 – $8,750

OriCell Therapeutics Co., Ltd.NCT06271252

Phase 2

Phase 2, Open Label, Multicenter Study of Pacritinib in Relapsed/Refractory T-cell Lymphoproliferative Neoplasms

The main purpose of this study is to determine the effectiveness of the study drug pacritinib in people with relapsed or refractory lymphoproliferative disorde…

T-Cell NeoplasmLymphoproliferative Disorders

Estimated

~$10 – $6,250

University of Michigan Rogel Cancer CenterNCT04858256